To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Madrigal Pharmaceuticals is ...

As if shutting the government down in the name of health insurance subsidies wasn’t enough, a federal judge took an axe to another meaningful way to reform American health policy – auditing bad actors ...

Madrigal (shoulder) cleared waivers and opted for free agency Thursday. Madrigal missed the full 2025 campaign after undergoing surgery in February to repair a fractured left shoulder. The infielder, ...

Shares of Madrigal Pharmaceuticals (MDGL) traded sharply higher for the second straight session on Wednesday after Cantor Fitzgerald upgraded the company, arguing that the commercial rollout of its ...

Madrigal Pharmaceuticals shares were 12% higher, at $460.63, after company's third-quarter revenue jumped on sales of Rezdiffra. The stock hit its 52-week high of $464.98 earlier in the session, and ...

St. Louis is crowned Premier League MLP Cup champions for 2025. Clockwise from the upper left: Gabe Tardio, Anna Bright, Kate Fahey, and Hayden Patriquin. The Cup is a throwback to the old days of MLP ...

Madrigal Pharmaceuticals is reiterated as a Strong Buy, driven by Rezdiffra's rapid US launch and recent European approval. Q2 2025 saw Rezdiffra sales reach $213M and >23,000 patients, with Q3 ...

In season two of the hit Netflix series, werewolf Bruno brings some normal high school drama into a mythical outcast world at Nevermore Academy. By Carly Thomas Associate Editor That’s where Noah B.

Forbes contributors publish independent expert analyses and insights. Hugh McIntyre covers music, with a focus on the global charts. Bruno Mars and Lady Gaga’s “Die With a Smile” ties “Uptown Funk” as ...

July 30 (Reuters) - U.S. drugmaker Madrigal Pharmaceuticals (MDGL.O), opens new tab has struck a licensing deal with CSPC Pharmaceutical Group (1093.HK), opens new tab that could be worth more than $2 ...

Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its approved fatty liver disease med Rezdiffra. The GLP-1 drug ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Madrigal Pharmaceuticals inks $2 ...